Samsung has officially entered the Chinese medical circle. What is the operation?

[China Pharmaceutical network industry trends] recently, Sansheng pharmaceutical and Samsung bioepis, a global biopharmaceutical giant, reached a cooperation agreement to conduct the clinical research, development and commercialization of several biological similar drugs in China, including bevacizumab biological similar drugs for metastatic colorectal cancer and non-small cell lung cancer in China I believe that many people are familiar with Samsung bioepis, but also know that the Korean mobile phone brand, which used to have hundreds of millions of users, has become the yellow flower of yesterday In fact, Samsung bioepis not only sells mobile phones, but also involves finance, machinery, chemistry and other fields This time, Samsung bioepis and Sansheng pharmaceutical cooperated to enter the Chinese pharmaceutical circle, which is an important layout for the biomedical field In recent years, cross-border and cross-border marriage of domestic and foreign pharmaceutical enterprises is not uncommon For example, on January 8, 2019, Takeda pharmaceutical announced the completion of the acquisition of shire, saying that it would focus on core business areas such as cancer, digestion, neuroscience, rare diseases and blood products (PDT) in the future, and jointly build a global biopharmaceutical company headquartered in Japan; on the evening of January 3, 2019, Bristol Myers Squibb announced that it would plan to build 74 billion US dollars (about 50.84 billion RMB ）After the acquisition of new base medicine, BMS will acquire multiple pipeline assets of new base in the fields of tumor, immunity and inflammation Through strong marriage, leading pharmaceutical enterprises can form complementary advantages and achieve win-win results According to the industry, in the context of broad prospects for the pharmaceutical industry, with the rising cost of R & D in the global pharmaceutical industry, China has a good R & D environment and policies, so it attracts more foreign pharmaceutical giants So what kind of sparks will be generated in the field of medicine when Samsung bioepis and Sansheng pharmaceutical are married? According to the public information, Samsung bioepis mainly develops biological analogues in research pipeline, including immunology, oncology, ophthalmology, hematology and other different fields In terms of products, at present, the company has 4 approved and listed bio similar drug products in Europe, including enalapril, infliximab, adalimumab and trastuzumab; in the United States, the listed bio similar drug products include infliximab, in addition, the research products of adalimumab and trastuzumab are under approval It can be seen that its product R & D ability cannot be underestimated In terms of marketing, Samsung bioepis cooperates with mature pharmaceutical companies such as Biogen company and Merck & Co company in the United States and has better resources Looking at China's Sansheng pharmaceutical, it involves the fields of biopharmaceutical, such as tumor, autoimmune disease, kidney disease, etc., and its main products include tebio, yisepu and yibio Industry data show that in the first half of 2018, tebiao's market share in the treatment of thrombocytopenia was 64.4% The market share of yisaipu in tumor necrosis factor inhibitor products is 64.9% It can be seen that its main products occupy a dominant position in the market In addition, Sansheng pharmaceutical is also committed to the research and development of innovative drugs At present, there are 32 products under development, 19 of which are monoclonal antibodies or biological drugs Combined with the product R & D and production capacity of the two enterprises and the advantages of local market resources, this cooperation will accelerate the clinical R & D of biological similar drugs in China, and bring better safe and affordable treatment options for patients Dr Lou Jing, chairman and executive officer of Sansheng pharmaceutical, said, "Sansheng pharmaceutical will continue to strengthen its leading position in the field of biopharmaceuticals through internal R & D and strategic cooperation, so as to promote high-quality urgently needed products to the Chinese and international markets more quickly." According to the cooperation agreement, Samsung bioepis will be responsible for the production and supply of products, and carry out a series of cooperation with Sansheng pharmaceutical, including clinical development, registration and commercialization in China Samsung bioepis will receive advance payment and product supply income from Sansheng pharmaceutical, and will be eligible for relevant clinical and regulatory milestone payments No further financial terms have been disclosed.